Experts say the pauses of trials of vaccines from Johnson & Johnson and AstraZeneca and a treatment from Eli Lilly demonstrate the system to protect participants’ safety is working as intended. ADAD“I certainly think it’s standard to limit information until more details are known,” said an investigator for the 60,000-person Johnson & Johnson trial, who spoke on the condition of anonymity to discuss the issue frankly. The investigator said the company had not yet provided details about the reason for the pause to experts leading the trials. “We need to eventually know more details if they expect people to continue to enroll at the rates they expect,” the investigator added. The pauses also underscore why it is dangerous to predict when a particular vaccine will be ready for public use, he added.

Source: Washington Post October 13, 2020 15:38 UTC